期刊文献+

支气管哮喘急性发作期超敏C-反应蛋白、白细胞、中性粒细胞比例检测的意义及比较 被引量:2

Clinical Significance of Detection of High Sensitivity C-reactive Protein,WBC,Neurocyte Percent in Serum in Acute Asthmatic Period
原文传递
导出
摘要 目的:探讨超敏C-反应蛋白(hs-CRP)、血白细胞总数(WBC)、中性粒细胞比例(N%)在支气管哮喘(简称哮喘)急性发作期诊治中的临床意义。方法:分析60例患者治疗前及自觉症状缓解时hs-CRP、WBC、N%动态变化情况,观察上述指标在急性发作期的阳性率以及自觉症状缓解时的阴性率。结果:①hs-CRP、N%、WBC在自觉症状缓解时均明显低于哮喘急性发作期(P<0.05);②哮喘患者急性发作期hs-CRP、N%阳性率均高于WBC阳性率,且与后者比较均具有统计学差异(P<0.05);③哮喘患者经治疗自觉症状缓解时hs-CRP、WBC阴性率均高于N%阴性率,且与后者比较均具有统计学差异(P<0.05)。结论:血清hs-CRP既可作为哮喘患者急性发作期感染的敏感指标,又是反映急性发作期治疗效果的早期评判指标,比WBC、N%更迅速、敏感。 Objective: To investigate the clinical significance of hs-CRP, WBC, Neurocyte Percent (N%)in the diagnosis and treatment in acute asthmatic period. Methods: The changes of serum hs-CRP, WBC count, N% in 60 patients with asthma in acute episode period before therapy and when feeling symptoms relief after therapy were retrospectively analyzed and summarized ;and their positive rate in acute episode period and their negative rate when feeling symptoms relief was observed . Results:(1) The levels of hs-CRP,WBC count,N% in patients with asthma when feeling symptoms relief is obviously lower than that in acute episode period( P 〈 0. 05); (2) The positive rate of hs-CRP and N% in patients with asthma in acute episode period is higher than that of WBC, and the difference was obvious (P〈0.05); (3) the negative rate ofhs-CRP and WBC count in patients with asthma when feeling symptoms relief after therapy is higher than that of N%, and the difference was obvious ( P〈0.05); Conclusion: Serum hs-CRP can be as a sensitive index in detecting the infection in patients with asthma in acute episode period, also be an index in early evaluating the therapeutic efficacy of asthma in acute episode period, and is more sensitive and quicker compared with WBC,N%.
出处 《现代生物医学进展》 CAS 2011年第13期2540-2542,共3页 Progress in Modern Biomedicine
  • 相关文献

参考文献16

  • 1支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[J].中华结核和呼吸杂志,2008,31(3):177-185. 被引量:2543
  • 2Global Strategy for asthmas management and prevention [DB/OL]. Hamilton: GINA Executive Committee, 2006[2007-7-11].http://www. ginasthma.com.
  • 3Reny JL, Vuagnat A, R ant C, et al. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables[J]. Crit Care Med, 2002, 30: 529-535.
  • 4Dong Q, W right JR. Expression of C-reactive protein by alveolar macrophages [J]. Immunol 1996, 156:4815-4820.
  • 5Taylor DR. Risk assessment in asthma and COPD: a potential role for biomarkers? [J]. Thorax, 2009, 64 (3) : 261-264.
  • 6Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD [J]. Curr Opin Pharmacol,2008, 8 (3) : 222-235.
  • 7Jaye D L, Waites KB. Clinical applications of C-reative protein in Pediatrics [J]. Pediatr Infect Dis, 1997, 16:735.
  • 8Gambino R. C- reactive protein undervalued, underutilized [J]. Clin Chem, 1997, 43(11) : 2017.
  • 9Korppi M, Heiskanen Kosma J, Leinonen M. White blood cell s, Creactive protein and erythrocyte sedimentation rate in pneumococcal pneumonia in children[J]. Eur Respir, 1997, 10(5) : 1125.
  • 10Pepys MB, Tennent GA. Targeting C-reactive protein for the treatment of cardiovascular disease[J]. Nature,2006,440:1217-1 221.

共引文献2542

同被引文献22

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部